Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccineMark S. Riddle, Edwin V. Oaks, Chris Soltis et al.|Vaccine|2011Cited by 79
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Stephen J. Thomas, Rafael De La Barrera et al.|The Journal of Infectious Diseases|2020Cited by 24
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael Koren, Kayvon Modjarrad, O.S. Adedeji et al.|The Lancet Infectious Diseases|2023Cited by 23
Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Alexander C. Schmidt, Rafael De La Barrera et al.|American Journal of Tropical Medicine and Hygiene|2020Cited by 17
Phase 1 clinical trial of Hantaan and Puumala virus DNA vaccines delivered by needle-free injectionJay W. Hooper, Trevor Wellington, Matthew Josleyn et al.|npj Vaccines|2024Cited by 11